SCHEMBL6899392

SCHEMBL6899392

COCOc1c(Br)ccc(OC)c1OCOC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
L3MBTL1 Q9Y468 4/20 0.40
HPGD P15428 3/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
TUBB1 Q9H4B7 2/20 0.38
NQO2 P16083 2/20 0.36
ERN1 O75460 1/20 0.36
KDM4E B2RXH2 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
PTPN1 P18031 1/20 0.35
LARS1 Q9P2J5 2/20 0.35
ALDH1A1 P00352 2/20 0.34
F2RL3 Q96RI0 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14736781 0.94 TUBB1 (0.40) MAPTL3MBTL1HPGDLMNAMAPK1
SCHEMBL2589218 0.86 PDE4D (0.41) MAPTL3MBTL1HPGDLMNAMAPK1
SCHEMBL2588591 0.85 MAPT (0.34) MAPTL3MBTL1HPGDLMNAMAPK1
SCHEMBL2591598 0.84 ERN1 (0.47) MAPTHPGDLMNAMAPK1TUBB1
SCHEMBL7942502 0.83 SMN1; SMN2 (0.50) MAPTL3MBTL1HPGDLMNAMAPK1
SCHEMBL2583910 0.82 NCOA1 (0.40) MAPTL3MBTL1HPGDLMNAMAPK1
SCHEMBL2591433 0.79 ALOX5AP (0.34) MAPTHPGDTUBB1PTPN1F2RL3
SCHEMBL2589018 0.78 BACE1 (0.35) TUBB1NQO2TDP1PTPN1F2RL3
SCHEMBL31166726 0.78 ALOX5AP (0.35) MAPTKDM4EPTPN1ALDH1A1F2RL3
SCHEMBL23041040 0.77 MEN1 (0.43) MAPTL3MBTL1MAPK1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6777578-B2 INHIBITOR OF TUBULIN POLYMERIZATION; ANTINEOPLASTIC ACTIVITY ARIZONA BOARD OF REGENTS 2004-08-17 US disclosed
US-20030220304-A1 Hydroxyphenstatin and the prodrugs thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220304-A1 Hydroxyphenstatin and the prodrugs thereof TK1, TUBB8, PHPT1 MAPT 452/4885L3MBTL1 114/4885HPGD 2110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.